1. Aurobindo, Cipla, Viatris in licensing pact with MPP(Medicine Patent Pool) to make ViiV's HIV preventive therapy.
2. Lotus Surgicals will be acquired for Rs 348 Crore by Premji Invest and Tube Investments in partnership .
3. Eris acquires 9 dermatology brands from Dr. Reddy’s for Rs 275 Crore.
4. Glenmark enters exclusive US distribution pact with Cediprof for FDA-approved products.
5. Sun Pharma completes acquisition of Concert Pharmaceuticals of Lexington Massachusetts.
6. Cipla to sell 51% Stake in Uganda arm for US$25-30 Million.
7. Coya Therapeutics, of Houston TX, announces an Agreement with Dr. Reddy’s to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases.
8. Australian Clinical Labs offers to buy Healius for US$1 Billion.
9. Norwegian company has submitted a cash offer to acquire all shares in Swedish Sensidose for approximately 75 million SEK.
10. Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates.
11. Radiopharm Theranostics to acquire Pharma15 Corp for US$4 Million.
12. Teijin Pharma inks exclusive license deal with Novartis for a pre-clinical candidate for proteinuric kidney diseases.
13. Kyorin sub-licenses Vibegron, a therapeutic agent for overactive bladder (OAB), to Sumitomo Pharma.
14. Biovian and Remedium collaborate on AAV gene therapy.

1. Aagami completed successful DCAT 2023 in New York City (March 20–23) with more than 20 one-to-one strategic meetings with decision makers.
2. Aagami is attending BIO International Convention (BIO) 2023 (June 5-8). The one-on-one partnering system is open now. Please send your meeting requests in advance.

For Partnering/Licensing/ Investment:

1. Licensing/Co-development: Easy to apply world’s First Transdermal Tizanidine Patch for the Management of Spasticity. Impressive Phase 1 results. Ready to initiate Phase 2.
2. Lidocaine 10% Topical Patch; NDA approval expected in Q4 of 2023. (Licensing for US available). Made using Proprietary drug formulation technology, ILTS® (Ionic Liquid Transdermal Technology). Indication: the treatment of PHN (postherpetic neuralgia)
3. Midwest US based Pharma’s Phase 2 stage First-in-Class Non-Opioid Analgesic for both chronic and acute Pain Relief – Seeking funding/licensing/co-development partnerships.
4. A single (monovalent) vaccine for Targeting Salmonella, ETEC / E. coli, Campylobacter, Shigella. Fulfills an unmet need for treating Bacterial Dysentery. Seeking funding/licensing/co-development partnerships.
5. $40 Million Series C: On the market, US FDA approved novel portable MRI Guided Treatment, Diagnosis and Screening, for Urology applications. California based client.

For Acquisition:

1. Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc. for Next-generation biologics and substantial returns.